Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Kenji Kuwabara"'
Autor:
Hitomi Morihara, Tomomi Yamada, Yumi Tona, Marina Akasaka, Hirohisa Okuyama, Natsumi Chatani, Satomi Shinonome, Azumi Ueyama, Kenji Kuwabara, Yasushi Fujio
Publikováno v:
PLoS ONE, Vol 19, Iss 8, p e0305984 (2024)
Inhibiting the cytotoxic T-lymphocyte-associated protein-4 (CTLA-4)-mediated immune checkpoint system using an anti-CTLA-4 antibody (Ab) can suppress the growth of various cancers, but the detailed mechanisms are unclear. In this study, we establishe
Externí odkaz:
https://doaj.org/article/b1f8393907fc4471bd1ddd6927a36cd1
Autor:
Yasuhiko Tomita, Kenji Kuwabara, Shingo Furue, Kazushige Tanaka, Katsutoshi Yamada, Masahiko Ueno, Takashi Ono, Toshiyuki Maruyama, Tetsuo Ajiki, Hirohiko Onoyama, Masahiro Yamamoto, Yozo Hori
Publikováno v:
Journal of Pharmacological Sciences, Vol 96, Iss 2, Pp 144-154 (2004)
We investigated the efficacy of a potent inhibitor of secretory phospholipase A2 (sPLA2), S-5920/LY315920Na, in an experimental model of acute pancreatitis in rats. Combined intraductal injection of sodium taurocholate (5 mg/rat) and porcine pancreat
Externí odkaz:
https://doaj.org/article/0a9c6784bc294695861d82278beec6b6
Autor:
Yoshino Ishioka, Yumi Tona, Wataru Nogami, Ryu Kanzaki, Hajime Yamada, Soichiro Funaki, Mitsunobu Matsumoto, Hidekazu Tanaka, Taisei Nomura, Yasushi Shintani, Kenji Kuwabara, Shigeki Adachi, Meinoshin Okumura, Soichi Tofukuji, Yoko Yamamoto
Publikováno v:
Cancer Research. 79:372-372
Despite the success of immune checkpoint therapy, most non-small cell lung cancer (NSCLC) patients still receive conventional chemotherapy. Overcoming chemotherapy resistance by identifying specific targets should improve cancer treatment and patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a1caea3a6d34cdc612c7844a075b485
https://doi.org/10.1158/1538-7445.am2019-372
https://doi.org/10.1158/1538-7445.am2019-372
Autor:
Wataru Nogami, Keiji Dohi, Hajime Yamada, Itsuki Oshima, Tomomi Kurino-Yamada, Kenji Kuwabara, Minoru Hasegawa, Hiroshi Yoshida, Koji Takahashi, Koji Sugiyama, Motoji Kitaura, Yoshinari Gahara
Publikováno v:
Experimental Hematology. 59:30-39.e2
Lusutrombopag (S-888711), an oral small-molecule thrombopoietin receptor (TPOR) agonist, has gained first approval as a drug to treat thrombocytopenia of chronic liver disease in patients undergoing elective invasive procedures in Japan. Preclinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1a8aa8c87b0893cddf1a6763443ffeb
https://doi.org/10.1016/j.exphem.2017.12.005
https://doi.org/10.1016/j.exphem.2017.12.005
Autor:
Makoto Todo, Tomiyoshi Aoki, Tetsuo Asaki, Shinji Ohmachi, Kenji Kuwabara, Kohji Murakami, Yukiteru Sugiyama, Taisuke Hamamoto
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 18:2128-2132
A new series of 1,3-dioxane-2-carboxylic acid derivatives was synthesized and evaluated for agonist activity at human peroxisome proliferator-activated receptor (PPAR) subtypes. Structure-activity relationship studies led to the identification of 2-m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fa343fd698e8684a49e6f0eb0a4688c
https://doi.org/10.1016/j.bmcl.2008.01.086
https://doi.org/10.1016/j.bmcl.2008.01.086
Autor:
Yukiteru Sugiyama, Taisuke Hamamoto, Keiichi Kuwano, Tetsuo Asaki, Kenji Kuwabara, Tomoko Niwa
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 17:6588-6592
A series of prostacyclin receptor agonists was prepared by modifying the central heteroaromatic ring of lead compound 2 , and a docking study was performed to investigate their structure–activity relationships by using a homology-modeled structure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::837597060713905d323bf359bd6dbdcc
https://doi.org/10.1016/j.bmcl.2007.09.066
https://doi.org/10.1016/j.bmcl.2007.09.066
Publikováno v:
Phytomedicine. 14:465-472
Inflammation is a common finding in benign prostatic hyperplasia (BPH). The phytotherapeutic agent eviprostat is a popular treatment for BPH in Japan and Germany. This agent consists of five components; four are extracted from Chimaphila umbellata, P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::971d37c4ed55da4d13fa4ae16723fc9a
https://doi.org/10.1016/j.phymed.2007.04.006
https://doi.org/10.1016/j.phymed.2007.04.006
Autor:
Tetsuo Asaki, Kenji Kuwabara, Taisuke Hamamoto, Kaori Okubo, Tetsuhiro Yamada, Asami Hashino, Keiichi Kuwano
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 322:1181-1188
Prostacyclin (PGI(2)) and its analogs are useful for the treatment of various vascular disorders, but their half-lives are too short for widespread clinical application. To overcome this drawback, we have synthesized a novel diphenylpyrazine derivati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80a9f71c0f437a504068ecec82f3f97d
https://doi.org/10.1124/jpet.107.124248
https://doi.org/10.1124/jpet.107.124248
Autor:
Tetsuo Ajiki, Katsutoshi Yamada, Masahiko Ueno, Kenji Kuwabara, Toshiyuki Maruyama, Shingo Furue, Kazushige Tanaka, Takashi Ono, Yozo Hori, Hirohiko Onoyama, Masahiro Yamamoto, Yasuhiko Tomita
Publikováno v:
Journal of Pharmacological Sciences, Vol 96, Iss 2, Pp 144-154 (2004)
We investigated the efficacy of a potent inhibitor of secretory phospholipase A2 (sPLA2), S-5920/LY315920Na, in an experimental model of acute pancreatitis in rats. Combined intraductal injection of sodium taurocholate (5 mg/rat) and porcine pancreat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07c146d92816cb147dea406e5ca9b976
http://www.sciencedirect.com/science/article/pii/S1347861319323564
http://www.sciencedirect.com/science/article/pii/S1347861319323564
Autor:
Kouji Nomura, Yozo Hori, Takashi Ono, Hitoshi Arita, Hirokuni Jyoyama, Yasuhiko Tomita, Katsutoshi Yamada, Isao Okayasu, Kenji Kuwabara, Shingo Furue, Mika Kobayashi, Masahiko Ueno, Isao Teshirogi
Publikováno v:
European Journal of Pharmacology. 472:147-158
Although group IIA phospholipase A(2) has been suggested to be implicated in inflammatory bowel disease, its pathophysiological role in colitis remains unclear. We investigated whether group IIA phospholipase A(2) had pro-inflammatory roles in dextra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4e7f9f98a652c3fd403776c96f69c4e
https://doi.org/10.1016/s0014-2999(03)01859-4
https://doi.org/10.1016/s0014-2999(03)01859-4